Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
    • Integrated Projects
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Our Events
    • Market Activity
    • Press Events
  • Contact

Epigenetic Sequencing Using Enzymatic Detection Method

Home Press Events
NextPrevious

Epigenetic Sequencing Using Enzymatic Detection Method

By medicilon | Press Events | 10 October, 2018 |

Investigators at the University of Pennsylvania’s (UPenn) Perelman School of Medicine have provided a novel method for sequencing epigenetic modifications using 1,000-fold less DNA than the current gold standard technique. The UPenn researchers believe that their novel method could pave the way for better detection of cancer and other diseases in the blood. Findings from the new study were published recently in Nature Biotechnology through an article titled “Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase.”

 

 

The epigenetic chemical groups mark one of the four DNA “letters” in the genome, and it is differences in these marks along DNA that control which genes are expressed or silenced. To detect disease earlier and with increased precision, researchers have a growing interest in analyzing free-floating DNA in settings in which there is a limited amount, such as that extruded from tumors into the bloodstream.

 

“We’re hopeful that this method offers the ability to decode epigenetic marks on DNA from small and transient populations of cells that have previously been difficult to study, in order to determine whether the DNA is coming from a specific tissue or even a tumor,” explains senior study investigator Rahul Kohli, M.D., Ph.D., an assistant professor of biochemistry and biophysics, and medicine at UPenn.

 

Scientists have investigated these DNA modifications over the last two decades to understand better and diagnose an array of disorders, most notably cancer. In recent years, the major methods used to decipher the epigenetic code have relied on a chemical called bisulfite. While bisulfite has proven useful, it also presents major limitations: it is unable to differentiate the most common modifications on the DNA building block cytosine, and more significantly, it destroys much of the DNA it touches, leaving little material to sequence in the lab.

 

This newly described method – given the moniker ACE-seq – builds on the fact that a class of immune-defense enzymes, called APOBEC DNA deaminases, can be repurposed for biotech applications. Specifically, the deaminase-guided chemical reaction can achieve what bisulfite could do, but without harming DNA.

 

“This technological advance paves the way to better understand complex biological processes such as how the nervous system develops or how a tumor progresses,” notes co-senior study investigator Hao Wu, Ph.D., an assistant professor of genetics at UPenn.

 

Using this method, the team showed that determining the epigenetic code of one type of neuron used 1,000-times less DNA than required by the bisulfite-dependent methods. From this, the new method could also differentiate between the two most common epigenetic marks, methylation, and hydroxymethylation.

 

“We were able to show that sites along the genome that appear to be modified are in fact very different in terms of the distribution of these two marks,” Dr. Kohli concludes. “This finding suggests important and distinctive biological roles for the two marks on the genome.”

No tags.

Related Post

  • Happy Chinese New Year from Medicilon!

    Read more

  • Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China

    Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China. Medicilon CEO Chun-Lin Chen gaveRead more

  • Warmest Holiday Season Greeting From Medicilon!

    Dear Clients, Collaborative Partners and Friends, As the end of year is approaching, we would likeRead more

  • Improved Humanized Mice Enhance Vaccine Development

    Every animal model of disease comes with its own unique set of drawbacks. Yet, scientists continuallyRead more

  • Cancer Drug Discovery Gets Boost from Novel Proteomics Platform

    Scientists at the Van Andel Research Institute have developed a novel biochemical platform to research aRead more

  • Staph Genes That Turn Commensal to Killer Identified

    Don’t be alarmed, but a bacterium that could turn deadly is on your skin right now.Read more

  • Method Predicts Exact Mutations CRISPR Gene Editing Can Introduce into a Cell

    The largest study of CRISPR action to date has developed a method to predict the exactRead more

  • Two-Pronged Approach Shows Promise against Drug-Resistant Cancers

    Researchers at the University of California, San Francisco (UCSF) report that they have discovered why someRead more

NextPrevious

News

  • Our Events
  • Market Activity
  • Press Events

Tags

Bio-forum (1) Cooperation (1) Experience (1) Strategy (1)

Top Posts

  • 14 February, 2017

    IND Enabling Studies FDA

  • 14 August, 2017

    Factors Affecting Pharmacokinetics of Drugs

  • 14 October, 2016

    Preclinical Drug Development Process

  • 7 February, 2017

    Target Identification and Validation in Drug Discovery

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry Services
  • Biology Services
  • Bioanalytical Services
  • Drug Safety Evaluation
  • Formulation Development Services
  • Pharmacology Services
  • Pharmacokinetic Services
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.
Email: Marketing@medicilon.com.cn
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
    • Integrated Projects
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Our Events
    • Market Activity
    • Press Events
  • Contact
Medicilon Inc